molecular-glues
(4)
Rapafusyn Pharmaceuticals
Rapafusyn Pharmaceuticals is a Baltimore-based, clinical-stage drug discovery company spun out of Johns Hopkins University. Its RapaGlue platform designs non-degrading, cell-permeable macrocyclic molecular glues that modulate hard-to-drug intracellular and transmembrane targets - drawing on a proprietary DNA-encoded library of more than 8 billion compounds and machine learning for target selection. The lead program, RAP-0001, is a selective ENT1 inhibitor advancing toward IND-enabling studies for the prevention of acute kidney injury in cardiac surgery patients, with a broader pipeline spanning oncology, immunology, and pain.
Drug Hunter
Drug Hunter is a Boston-based knowledge platform for the scientists who turn molecules into medicines. Founded in 2018 by former Genentech chemist Dennis X. Hu, it distills scientific literature, patents, and early disclosures into searchable, expert-curated insights - molecule search, patent search, courses, flash talks, and a mobile app. More than 200 R&D organizations, including Eli Lilly, Biogen, Merck KGaA, Isomorphic Labs, and the NIH, rely on it. In September 2025 the company raised a seed round led by Teamworthy Ventures.
Plexium
Plexium is a San Diego precision medicine company designing small-molecule protein degraders - monovalent direct degraders and molecular glues - that switch off disease-driving proteins traditionally considered undruggable. Its DELTA Discovery platform runs ultra-high-throughput cell-based screening to find and optimize new degrader chemistry across cancer and neurological disease.
Fathom Therapeutics
Fathom Therapeutics (formerly Atommap) is a New York and Boston based biotech building Microcosmos, a drug-design engine that fuses quantum chemistry and AI to simulate how proteins actually move inside living cells. By modeling motion instead of static snapshots - reportedly up to 10,000x faster than conventional simulation - the company hunts for the fleeting binding pockets that make 'undruggable' targets druggable, then designs small molecules, degraders, and molecular glues against them. In April 2026 it raised a $47M oversubscribed Series A led by Sutter Hill Ventures.